Literature DB >> 7032290

High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer.

D Douer, R E Champlin, W G Ho, G P Sarna, J H Wells, P R Graze, M J Cline, R P Gale.   

Abstract

Fourteen patients with resistant cancers received high-dose chemotherapy and total body irradiation followed by rescue with autologous cryopreserved bone marrow cells. In seven patients, disease has remained in remission for periods up to two years. These data indicate that effectiveness of high-dose combined-modality therapy and bone marrow autotransplantation in patients with resistant cancer. The high incidence of non-marrow toxicity may be reduced by the use of this modality before patients have received extensive therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7032290     DOI: 10.1016/0002-9343(81)90316-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma.

Authors:  I E Smith; B D Evans; S J Harland; B A Robinson; J R Yarnold; J G Glees; H T Ford
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 2.  High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors.

Authors:  C F LeMaistre; W A Knight
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation.

Authors:  S Li; R Champlin; J H Fitchen; R P Gale
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

4.  Phase-I-II study of high-dose melphalan and autologous marrow transplantation in adult patients with poor-risk non-Hodgkin's lymphomas.

Authors:  B Mascret; D Maraninchi; J A Gastaut; D Baume; G Sebahoun; C Lejeune; G Novakovitch; D Sainty; N Horchowski; N Tubiana
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.